ALK-positive anaplastic large cell lymphoma

This early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…

This phase 2 trial tests a new combination treatment for a rare type of lymphoma (CD30-positive peripheral T-cell lymphoma). It combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal is to see if this approach improves the number of patients who achie…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …

This study tests the immunotherapy drug nivolumab in 45 children and adults with a rare blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment. Participants are split into two groups: those with active disease to see if th…